Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Addex Therapeutics (ADXN) Return on Sales (2019 - 2025)

Addex Therapeutics' Return on Sales history spans 7 years, with the latest figure at 0.14% for Q4 2025.

  • On a quarterly basis, Return on Sales fell 3.0% to 0.14% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.15%, a 43.0% decrease, with the full-year FY2025 number at 0.04%, down 26.0% from a year prior.
  • Return on Sales came in at 0.14% for Q4 2025, down from 0.07% in the prior quarter.
  • The five-year high for Return on Sales was 1.25% in Q2 2024, with the low at 0.52% in Q4 2023.
  • Historically, Return on Sales has averaged 0.04% across 5 years, with a median of 0.06% in 2023.
  • Biggest five-year swings in Return on Sales: tumbled -63bps in 2023 and later skyrocketed 128bps in 2024.
  • Year by year, Return on Sales stood at 0.11% in 2021, then surged by 196bps to 0.11% in 2022, then tumbled by -590bps to 0.52% in 2023, then soared by 80bps to 0.11% in 2024, then crashed by -30bps to 0.14% in 2025.
  • Business Quant data shows Return on Sales for ADXN at 0.14% in Q4 2025, 0.07% in Q3 2025, and 0.11% in Q4 2024.